Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer

References

• Dodwell D, Williamson D. Beyond tamoxifen: Extended and late extended endocrine therapy in postmenopausal early breast cancer. Cancer Treat Rev 2008;34:137–44.
   PubMedGoogle Scholar
• Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M. Extended adjuvant endocrine therapy in breast cancer: Current status and future directions. Clin Breast Cancer 2008;8:411–7.
   PubMed Web of Science ®Google Scholar
• Josefsson ML, Leinster SJ. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: Meta-analyses of monotherapy, sequenced therapy and extended therapy. Breast 2010;19:76–83.
   PubMedGoogle Scholar
• Snoj N, Paridaens R, Cufer T. Current controversies in extended adjuvant endocrine therapy for early breast cancer. Curr Opin Oncol 2008;20:627–33.
   PubMedGoogle Scholar
• Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract 2010;6:243–6.
   PubMedGoogle Scholar
• Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006;71:1–9.
   PubMed Web of Science ®Google Scholar
• Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010;73:156–66.
   PubMed Web of Science ®Google Scholar
• Edge S, Byrd D, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th. New York: Springer; 2009.
   Google Scholar
• Sobin L, Gospodarowicz M, Wittekind C. UICC: TNM classification of malignant tumors. 7th. Oxford: Wiley-Blackwell; 2009.
   Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133–44.
   PubMed Web of Science ®Google Scholar
• Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15: 565–74; discussion 575–7.
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: A lesson for oncologists. Cancer 2007;109:832–9.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–97.
   PubMed Web of Science ®Google Scholar
• Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, . Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25:486–92.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, . Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–71.
   PubMed Web of Science ®Google Scholar
• Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, . Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007;99:1845–53.
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, . Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008;26:1965–71.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20: 1319–29.
   PubMed Web of Science ®Google Scholar
• Guth U, Huang DJ, Schotzau A, Zanetti-Dällenbach R, Holzgreve W, Bitzer J, . Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 2008;99:428–33.
   PubMed Web of Science ®Google Scholar
• Hong S, Didwania A, Olopade O, Ganschow P. The expanding use of third-generation aromatase inhibitors: What the general internist needs to know. J Gen Intern Med 2009; 24(Suppl 2):S383–8.
   PubMedGoogle Scholar
• Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, . Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120–8.
   PubMed Web of Science ®Google Scholar
• Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, . Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;20:431–6.
   PubMed Web of Science ®Google Scholar